Ribociclib is produced by which company?

Ribociclib/Calilon (Ribociclib) is developed and produced by Novartis (Novartis). It is one of the internationally important targeted drugs for hormone receptor-positive, HER2-negative advanced breast cancer. As a world-renowned multinational pharmaceutical company, Novartis has long been committed to the research and development of innovative anti-tumor drugs, and Riboxiclib is one of its key products in the field of oncology. With its ability to precisely inhibit the CDK4/6 signaling pathway, Riboxiclib is recommended in multiple international guidelines. Used in combination with endocrine therapy, it can further enhance the therapeutic response and enable patients to achieve more stable gains in disease control.

During the development of Riboxil, Novartis conducted multiple rounds of optimization on its molecular structure, metabolic characteristics and tolerability, so that the drug could be both effective and safe. Its research and development ideas stem from in-depth research on the cell cycle regulation mechanism of breast cancer. The emergence of CDK4/6 inhibitors has changed the traditional treatment path for hormone receptor-positive breast cancer, and is also regarded as one of the important advances in breast cancer treatment technology in the past decade. Relying on Novartis's comprehensive international clinical system, Riboxiclib has completed marketing registration in many countries. Data shows that it has stable pharmacokinetic characteristics in different populations. This is why many countries around the world have included it in clinical pathways.

Novartis has strong capabilities in the pharmaceutical supply chain, pharmaceutical quality and international distribution system, which enables Riboxil to maintain stable supply in most countries. At the same time, the company is also actively promoting the compliance access of drugs in various countries and regions, including promoting registration in Asia and providing more accessibility channels, etc., so that patients can obtain drugs in a more standard way. For domestic patients, Riboxiclib, as an imported targeted drug, has reliable quality, stability and international recognition, so it is often used by doctors in combined endocrine treatment programs.

Reference materials: https://us.kisqali.com/